©2025 Stanford Medicine
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Not Recruiting
Trial ID: NCT06855628
Purpose
The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).
Official Title
Assessment Of A Novel Metabolic Imaging Modalities As A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)
Stanford Investigator(s)
Lawrence D Recht
Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
* Any participant that consents to entry into the Phase II BPM31510 parent study (BPM31510IV-11)
* Women of childbearing potential must have a negative pregnancy test
* Ability to understand and the willingness to provide written informed consent.
Exclusion Criteria:
* Refuse to have an IV
* Allergy to MRI contrasts
* Diabetic patients who are taking insulin
Intervention(s):
other: [6,6-²H₂]-Glucose
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Lewis Naya
650-725-0379